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Małgorzata Mikulska,1 Anna Maria Raiola,2 Paolo Bruzzi,3 Riccardo Varaldo,2
Silvana Annunziata,2 Teresa Lamparelli,2 Francesco Frassoni,2 Elisabetta Tedone,2
Barbara Galano,2 Andrea Bacigalupo,2 Claudio Viscoli1Cytomegalovirus (CMV) infection and disease are important complications after hematopoietic stem cell
transplant, particularly after transplant from alternative donors. Allogeneic cord blood transplantation
(CBT) is being increasingly used, but immune recovery may be delayed. The aim of this study was to compare
CMV infection in CBTwith transplants from unrelated or mismatched related donors, from now on defined
as alternative donors. A total of 165 consecutive transplants were divided in 2 groups: (1) alternative donors
transplants (n 5 85) and (2) CBT recipients (n 5 80). Donor and recipient (D/R) CMV serostatus were
recorded. The incidence of CMV infection, its severity, timing, and outcome were compared. Median
follow-up was 257 days (1-1328). CMV infection was monitored by CMV antigenemia and expressed as
CMVAg positive cell/2 105 polymorphonuclear blood cells. There was a trend toward a higher cumulative
incidence of CMV infection among CBT than alternative donor transplant recipients (64% vs 51%, P 5 .12).
The median time to CMV reactivation was 35 days, and was comparable in the 2 groups (P 5 .8). The max-
imum number of CMV-positive cells was similar in the 2 groups (11 versus 16, P 5 .2). The time interval
between the first and the last positive CMV antigenemia was almost 4 times longer in CBT compared
with alternative donor transplants (109 vs 29 days, respectively, P5 .008). The incidence of late CMV infec-
tion was also higher in CBT (62% vs 24%, P\.001). The incidence of early and late CMV infection in CBTwas
similar to D2/R1 alternative transplants, and higher than in D1/R1 alternative transplants: early infection,
72% in CBT versus 69% in D2/R1 alternative versus 55% in D1/R1 alternative (P5 .21); and late infection,
67% in CBT versus 60% in D2/R1 alternative versus 7% in D1/R1 alternative (P\.001). Transplant-related
mortality and overall survival were similar between the groups: 34% versus 36% (P5 .6) and 54% versus 46%
(P 5 .3) for alternative transplant and CBT, respectively. Longer duration and higher incidence of late
CMV infection was seen in CBT patients, when compared with alternative donor transplants, whereas no
difference in mortality was observed. The duration and incidence of late CMV infection were similar
when D2/R1 CBTwere compared with D2/R1 alternative donor transplants.
Biol Blood Marrow Transplant 18: 92-99 (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: Cytomegalovirus, Cord blood transplant, Matched unrelated transplant, Alternative donor,
Serostatus, Late CMV infection1Division of Infectious Diseases, San Martino University
ital, Genoa, Italy; 2Division of Hematology and HSCT,
artino University Hospital, Genoa, Italy; and 3Clinical
miology Unit, National Institute for Cancer Research,
a, Italy.
isclosure: See Acknowledgments on page 98.
dence and reprint requests: Małgorzata Mikulska, MD,
on of Infectious Diseases, San Martino University
ital, L.go R. Benzi, 10-16132 Genoa, Italy (e-mail:
kulska@yahoo.com).
arch 31, 2011; accepted May 23, 2011
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2011.05.015INTRODUCTION
Cytomegalovirus (CMV) infection is an important
cause ofmorbidity andmortality after allogeneic hema-
topoietic stem cell transplant (HSCT), even in the era
of prophylaxis and preemptive treatment [1-3].
Without prophylaxis, the incidence of CMV infection
can be as high as 80% among CMV seropositive
HSCT recipients [3]. Moreover, the case-fatality rate
in case of end-organ disease, such as pneumonia, can
reach 50% [4]. Recipients of transplants from alterna-
tive donors (matched unrelated, mismatched related,
and cord blood) are at higher risk of CMV infection,
compared to transplants from a matched related
donor [3].
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increasingly been used as treatment for patients with
both malignant and nonmalignant disorders [5,6]. In
comparison with transplants from adult donors, CBT
offers the advantage of prompt availability of stem
cells for many recipients and safety of cell collection
[6]. Compared to the immune system of adults, the im-
mune system of cord blood is immature, a fact thought
to result in a higher risk of early infectious complica-
tions [6,7].
In the present study, we have analyzed the inci-
dence and temporal course of CMV infection, together
with transplant-related mortality (TRM) and overall
survival (OS), and compared it between 2 groups: re-
cipients of transplants from cord blood and from other
alternative donors.MATERIALS AND METHODS
Patients/Data Collection
A retrospective observational study of CMV reac-
tivation was performed in 165 consecutive patients
who underwent allogeneic HSCT from donors other
thanmatched related between January 1, 2006 andOc-
tober 15, 2009, at the HSCT Unit of San Martino
Hospital in Genoa. All data were acquired from a pro-
spectively collected computerized database and chart
review. The data of 80 CBT recipients were compared
with 85 alternative donor transplant recipients. CBT
graft had at least 4/6 in HLA-A or HLA-B antigens
or HLA-DRB1 alleles that were matched to the recip-
ient. Unrelated donors had at least 6/6 HLA-A, HLA-
B, or HLA-DRB1 alleles that were matched, whereas
related mismatched donors had 1 difference in antigen
on HLA-A or HLA-B loci.Transplantation Procedures and Management
of Infections
Transplantation was performed according to insti-
tutional protocols, and CBT was performed as intra-
bone procedure. All the procedures have been
described elsewhere [8-12]. Briefly, a standard graft-
versus-host disease (GVHD) prophylaxis consisted
of cyclosporin A (CsA) and methotrexate (MTX) ei-
ther at a normal (15 mg/m2 on day11 after transplan-
tation, 10 mg/m2 on days13,16, and111) or at a low
dose (10 mg/m2 on day11, 8 mg/m2 on days 13, 16,
and 111). CBT recipients received mycophenolate
mofetil (MMF) 15 mg/kg twice a day from day 11
to 128, instead of MTX. Rabbit antithymocyte glob-
ulin (ATG) (Thymoglobuline, Genzyme, Boston,
MA) at 6-10.5 mg/kg was administered as a part of
the conditioning regimen. All the patients received
CMV prophylaxis with foscarnet at 30 mg/kg twice
a day from day 27 to day 130, then at 90 mg/kg for5 days a week until day 1100. In case of CMV antige-
nemia with\4 cells positive, a monotherapy with ei-
ther gancyclovir (5 mg/kg twice a day) or foscarnet
(90 mg/kg twice a day) was started. If .4 neutrophils
were positive for CMV, a combined therapy with the
same drugs was administered and continued for at
least 14 days after negative CMV antigenemia, then
gancyclovir (5 mg/kg) and foscarnet (90 mg/kg) were
administered every other day for another 14 days.
The surveillance for CMV was performed twice
weekly for the first 100 days after HSCT, or longer
if any complications were present. CMV surveillance
was stopped in patients with a sustained remission of
underlying disease, with no steroid immunosuppres-
sive therapy for extensive GVHD and after at least
a month since the last positive antigenemia.
Definitions
The primary endpoint of this study was CMV infec-
tion after transplantation. CMV infection was defined
as a positive pp65CMVantigenemia, whichwas defined
as a $1 antigen-positive cell in a single slide; CMV
disease was defined as end-organ disease, such as pneu-
monia, gastrointestinal disease, hepatitis, etc., with
a documented CMV etiology [13,14]. The degree of
CMV antigenemia was expressed as the number of
CMV pp65 antigen-positive cells per 2  105 leuko-
cytes. For the evaluation of CMV antigenemia, 2 105
leukocytes were always analyzed, because the detection
limit was 1 CMV antigen-positive cell per 2  105 leu-
kocytes in this assay. LateCMV infectionwas defined as
occurring after 100 days from HSCT [15]. TRM was
defined as death because of any cause other than the
relapse of the underlying hematologic disease.
The underlying diseases were grouped into the fol-
lowing categories: (1) acute leukemia, (2) chronic mye-
loproliferative disorders (chronic myeloid leukemia,
myelofibrosis), (3) chronic lymphoproliferative disor-
ders (lymphoma, multiple myeloma, chronic lymphatic
leukemia), and (4) myelodysplastic syndrome, and
others, mostly severe aplastic anemia. The status of
the underlying disease at HSCT was classified as: (1)
first complete remission or inactive disease after the
first line of treatment, (2) second or following complete
remission or inactive disease after equal to or a greater
than second line of treatment, and (3) relapse or active
disease at the time of HSCT. An active underlying he-
matologic disease at transplantation was defined by the
presence of blast cells in the peripheral blood or by
persistent disease refractory to chemotherapy.
Statistical Analysis
Patients were divided into 2 groups, based on graft
source: (1) alternative transplants (matched unrelated
andmismatched related) and (2) CBT. The differences
between the groups were assessed by means of the
94 Biol Blood Marrow Transplant 18:92-99, 2012M. Mikulska et al.chi-square test for heterogeneity or Fisher exact test
when appropriate. Continuous variables were com-
pared with a nonparametric Mann-Whitney test.
The cumulative incidence of CMV infection,
GVHD, TRM, and OS were calculated by means of
the Kaplan-Meier method and compared with the
log-rank test. For CMV infection, cumulative inci-
dence was evaluated considering death without CMV
infection as a competing risk. The influence of vari-
ables on CMV reactivation was assessed in a logistic
regression model, where the dependent variable was
occurrence of CMV reactivation after transplantation.
For incidence data, 95% confidence intervals (95%CI)
were calculated. All P values are 2 sided; a P value of
#.05 was considered to be statistically significant.
The analyses were performed using the SPSS version
13.0 statistical package (SPSS, Inc., Chicago, IL).RESULTS
Patients’ Characteristics
Transplant recipient demographic characteristics,
by donor graft source, are shown in Table 1. The me-
dian age was 41 years (range: 17-71 years). The median
follow-up after HSCT was 254 days (range: 2-1169) in
CBT recipients and 257 days (range: 1-1328) in alter-
native donor transplants. GVHD prophylaxis included
CsA and MMF in all CBT recipients and in some re-
cipients of alternative transplant (9 of 85, 11%). Other
alternative donor transplants received CsA and MTX
(76 of 95, 89%). All patients received ATG as a part
of their conditioning regimens: The total dose ofTable 1. Baseline Characteristics of Study Patients
Variable Total (%), n 5165
Age at transplantation, yrs, median (range) 41 (17-71)
Sex, male 101 (61)
Diagnosis
Acute leukemia 90 (56)
CML/MF 19 (12)
MM/CLL 26 (16)
MS and SAA 30 (18)
Phase at transplantation
First complete remission 43 (26)
Complete remission $2nd 48 (29)
Active disease 74 (45)
Conditioning regimen
Myeloablative 118 (72)
Reduced intensity 47 (29)
CMV serostatus*
Missing 9 (6)
Recipient 2 20 (13)
Recipient + 136 (87)
D2/R2 15 (9)
D+/R2 5 (3)
D2/R+ 98 (60)
D+/R+ 38 (23)
CLL indicates chronic lymphocytic leukemia; CML, chronic myeloid leukemia; M
SAA, severe aplastic anemia; CMV cytomegalovirus.
*Available for 156 patients (94%).ATG for CBT recipients was 6 mg/kg (n 5 65) or
7.5 mg/kg (n 5 15), and for alternative donor trans-
plants 7.5 mg/kg (n 5 62) or 10.5 mg/kg (n 5 20).
No difference between the 2 groups was observed in
terms of gender, phase of disease, or CMV serostatus.
Overall, 140 patients (85%) achieved neutrophil
engraftment (88% in alternative transplant and 81%
in CBT, P 5 .2), 2 patients received a second HSCT
because of primary graft failure, and 23 died before
the engraftment. The median time to engraftment
was longer after CBT: 23 versus 18 days, P\ .001.
No statistical difference was found in the incidence
of acute GVHD (aGVHD) (grade 0-1 in 74% of alter-
native transplant patients and 80% of CBT, P5 0.16),
although only 1 patient in the CBT group developed
severe aGVHD versus 5 alternative transplant pa-
tients. Also, the incidence of chronic GVHD
(cGVHD) was similar in both groups (P 5 .93); and
approximately 20% of 111 patients who survived
more than 100 days after HSCT developed moderate
to severe cGVHD in both groups (12 of 59, 20% in al-
ternative transplant group and 12 of 52, 23% in CBT).CMV Infection and CMV Disease
Among 165 patients, 94 developed CMV infection
(cumulative incidence 57%, 95% CI 49%-65%).
There was a trend toward a higher incidence of
CMV infection in CBT recipients (64%, 95% CI;
53%-74%)with respect to alternative donor transplant
recipients (51%, 95% CI; 40%-61%), but the differ-
ence was not statistically significant (P 5 .12). This
was true also when the type and status of theAlternative donor, n 5 85 CBT, n 5 80 P value
45 (17-71) 39.5 (18-64) .04
52 (61) 49 (61) NS
.03
37 (44) 53 (66)
13 (15) 6 (8)
15 (18) 11 (14)
20 (24) 10 (13)
NS
22 (26) 21 (26)
20 (24) 28 (35)
43 (51) 31 (39)
<.001
50 (59) 68 (85)
35 (41) 12 (15)
6 (7) 3 (4)
12 (15) 8 (10) NS
67 (85) 69 (90)
7 (8) 8 (10)
5 (6) 0
29 (34) 69 (90)
38 (45) 0
F, myelofibrosis; MM, multiple myeloma; MS, myelodysplastic syndrome;
Figure 1. Cumulative incidence of CMV infection (180 days) in 2 types
of HSCT donors: alternative versus cord blood.
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men were adjusted for (data not shown). The 6-month
cumulative incidence of CMV infection in the 2
groups is outlined in Figure 1.
Detailed results of CMV infection are shown in
Table 2. The time interval between transplantation
and the first positive CMV antigenemia was similar
in both groups (median 35 days for alternative donor
transplant and 36 days for CBT, P 5 .8). In both
groups, the number of CMV-positive cells at the first
positive antigenemia was low (median 2 cells, P 5
.06). The maximum number of CMV-positive cells
was higher in CBT recipients; however, the difference
was not statistically significant (11 vs 16 cells, P 5 .2)
(Table 2).
The duration of CMV infection, that is, themedian
time between the first and the last positive antigenemia,
was significantly longer in CBT recipients than in the
alternative donor group (109 vs 29 days, P 5 .008,
Table 2). Figure 2 shows the percent of patients with
positive CMV antigenemia during the months follow-
ing HSCT, divided according to the type of donor.
Almost all patients who reactivated CMV (93/94,
99%) developed early CMV infection. A total of 111
patients had a follow-up of more than 100 days after
transplantation (for 3 of them, CMV serostatus was
missing; none of them developed CMV infection).Table 2. Characteristics of CMV Reactivation in 94 HSCT Recipien
Variable All Pa
CMV infection, number of patients (%) 9
Days between HSCT and the first positive antigenemia, median (range) 3
Number of CMV-Ag positive cells leukocytes at the first antigenemia,
median (range)
Peak number of CMV-positive cells leukocytes, median (range) 1
Days between the first and the last positive antigenemia, median (range) 7
CMV indicates cytomegalovirus; CBT, cord blood transplantation; HSCT, hemAmong them, 41% (46 of 111) developed late CMV in-
fection (45 both early and late infection, 1 late infec-
tion only). Late infection was significantly more
frequent after CBT than after alternative transplant
(32/52, 62% vs 14 of 59, 24%, respectively, P\ .001).
CMV disease was diagnosed in 5 patients (3%): 3
CBT recipients and 2 alternative transplant recipients.
Four patients developed pneumonia and 1 developed
encephalitis, and all of them died with or because of
CMV disease.
Influence of CMV Serostatus
Twenty patients were CMV seronegative, and 2 of
them (10%) developed CMV infection; 1 of 9 patients
for whom theD/RCMV serology was unknown devel-
oped CMV infection. Among 136 seropositive recipi-
ents, 91 (67%) reactivated CMV, and CMV infection
was more frequent after CBT (73%) than after alterna-
tive donor transplant (61%), but the difference was not
significant statistically (P 5 .16).
Subsequently, CMV seropositive patients were di-
vided according to donor serostatus in 3 groups: 69
CBT (all D2/R1), 29 D2/R1 alternative transplant,
and 38 D1/R1 alternative transplant. The incidence
of CMV infection in these 3 groups was, respectively,
72%, 69%, and 55% (P 5 .21) (Figure 3). The inci-
dence of early and late CMV infection according to
type of transplant andD/RCMV serostatus is outlined
in Table 3.
The duration of CMV positivity was 106 days
(range: 1-674) for CBT, 126 days (range: 1-794) for
D2/R1 alternative transplants, and 11 days (range:
1-249) for D1/R1 alternative transplants. The dura-
tion of CMV infections was significantly shorter in
D1/R1 alternative grafts when compared with D2/
R1 alternative grafts (P 5 .006) and CBT (P \
.0001), as outlined in Figure 4. The incidence of late
CMV infection was similar in the D2/R1 CBT (31
of 46, 67%) and D2/R1 alternative transplant groups
(12 of 20, 60%), and was significantly higher when
compared with D1/R1 alternative transplants (2/27,
7%; P\ .001) (Figure 5).
Outcome
At the end of the follow-up, 83 of 165 (50%) were
alive with a median follow-up of 257 days (range:ts
tients, n 5 165 Alternative Donor, n 5 85 CBT, n 5 80 P value
4 (57%) 43 (51%) 51 (64%) .06
5 (0-105) 35 (1-83) 36 (0-105) .8
2 (1-287) 3 (1-69) 2 (1-287) .06
1 (1-1000) 10 (1-180) 16 (1-1000) .20
9 (1-793) 29 (1-793) 109 (1-674) .008
atopoietic stem cell transplantation; CMV-Ag, CMV antigen.
Figure 2. Percent of patients with CMV infection during the first 12
months after transplantation, divided according to donor type.
Table 3. Overall and Late CMV Infection According to CMV
Serostatus and the Type of Donor
Variable CMV Infection* Late CMV Infection†
Alternative donor transplants
D2/R2 1/7 (14%) 0/6
D+/R2 0/5 0/5
D2/R+ 20/29 (69%) 12/20 (60%)
D+/R+ 21/38 (55%) 2/27 (7%)
Cord blood transplants
D2/R2 1/8 (13%) 1/4 (25%)
D+/R2 — —
D2/R+ 50/69 (73%) 31/46 (67%)
D+/R+ — —
CMV indicates cytomegalovirus.
*Reported for 156 patients with complete D/R CMV serology; among 9
patients with CMV D/R serology missing, 1 developed CMV infection.
†Data available for 108 patients with known CMV serostatus and with
follow-up longer than 100 days.
96 Biol Blood Marrow Transplant 18:92-99, 2012M. Mikulska et al.1-1328). OS was 50% (alternative transplant 54% and
CBT 46%, P 5 .28) and TRM was 35% (alternative
transplant 34% and CBT 36%, P 5 .64), and did not
differ between the groups. The rate of death from in-
fectious causes was similar in both groups (alternative
transplant 19% and CBT 24%, P 5 .45).
The OS in 94 patients with CMV reactivation was
similar in both groups (alternative donor, 22 of 43,
51%; CBT 29 of 51, 57%, P 5 .52). TRM in patients
with CMV reactivation was similar in alternative do-
nor group compared with CBT (33% vs 22%, respec-
tively, P 5 .25). The rate of patients deceased with
CMV infection detected within 30 days of death was
similar in both groups (alternative donor 11 of 43,
26%; CBT 12/51, 24%). There was no difference in
OS between D1/R1 and D2/R1 groups (P 5 .98).DISCUSSION
Themain findings of the study are: (1) CMV infec-
tion was a frequent event in our series of patientsFigure 3. Cumulative incidence of first CMV infection (180 days) in
seropositive HSCT recipients divided according to donor serostatus
and type of transplant.receiving transplants from donors other than matched
related; (2) CBT was associated with a moderate, not
statistically significant, increase in the incidence of
CMV infections compared with alternative transplants
and with a significantly higher rate of late CMV infec-
tions; (3) the incidence and duration of CMV infec-
tions were associated with donor CMV serostatus,
rather than with type of transplant, being almost iden-
tical in D2/R1 alternative transplants and D2/R1
CBT; (4) when compared with D1/R1 alternative
transplants, D2/R1 transplants, irrespective of donor
type, experienced modestly more early and signifi-
cantly more late CMV infections; and (5) the outcome,
in terms of CMV disease, TRM, and survival, was
comparable between CBT and alternative transplants.
The incidence of CMV infection after HSCT is
influenced largely by the type of transplant and
CMV serostatus [3]. Previous reports have found that
the CMV infection rate after transplantation from do-
nors other than matched related varied between 20%Figure 4. Median time (in days) between the first and last positive CMV
antigenemia in CMV seropositive HSCTrecipients divided according to
donor serostatus and type of transplant.
Figure 5. Cumulative incidence of late CMV infection in CMV seropos-
itive HSCTrecipients divided according to donor serostatus and type of
transplant. Note: Incidence of late (.100 days after transplant) CMV
infection, both in patients with and without previous early infection,
was evaluated in 108 patients who survived more than 100 days after
transplant.
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infection remain controversial, with the reported inci-
dence ranging from 21% to 100% [16-19]. Our data,
with an overall incidence of 57%, 51% for
alternative donors, and 64% for CBT, are similar to
what has been previously reported. In particular, the
incidence after CBT was only moderately higher
when compared with alternative donor transplants.
The timing and severity of the first CMV infection
was similar in both groups. However, important
differences between the groups were noted in the
duration of CMV infections and the incidence of late
infections. Indeed, the median time from the first to
the last positive CMV antigenemia was 4-fold longer
in CBT, and the incidence of late CMV infection
was almost 3-fold higher in CBT (24% vs 62%). In
the last ten years, late CMV infection and disease are
being increasingly reported in HSCT, although the
reasons for this increase are poorly understood
[3,20]. The use of gancyclovir prophylaxis, the
improvement in OS, long-term use of immunosup-
pressive treatments, and widespread use of alternative
donors reportedly induce dysfunction in CMV-
specific T cells and possibly predispose these patients
to late CMV infections [3,15,20]. What might be the
reasons for more CMV infections in the case of
CBT, both in terms of incidence of early or late
reactivation and its duration in our population? Two
groups of our patients were similar in terms of
antiviral prophylaxis and treatment, time of follow-
up, and the incidence of GVHD. Antilymphocyte
globulin causes T-lymphocyte depletion and has
been associated with the increased risk of viral infec-
tions [14]. However, for CBT, the dose of ATG was
lower than for other alternative donors; thus, thisfactor is unlikely to contribute to the higher incidence
of late CMV after CBT. Certainly, delayed immune re-
constitution may be 1 of the main factors, as CBT recip-
ients have significantly lower CD41 counts during the
first 6 months after HSCT, compared with other alloge-
neicHSCTrecipients [21]. In addition, at our center, the
median count of CD41 at 3months after transplantation
was 28 cells for CBT and 68 cells for unrelated donors
(unpublished data). Moreover, the function of T-cell
lymphocytes (expressed as interferon [IFN]-g produc-
tion after superantigen stimulation) was also found to
be severely impaired in CBT [21]. However, are there
factors other than immaturity of cord blood cells that
might have influenced the rate of CMV infection?
The role of donor serostatus in CMV infection is
controversial [14]. However, CMV-seropositive pa-
tients with CMV-seronegative donors might have an
increased risk of repeated CMV reactivations and
CMV disease, probably because of a lack of protective
CMV-specific immunity transferred from donor to re-
cipient [15,22]. Therefore, we analyzed if donor CMV
serostatus might be associated with prolonged and
repeated CMV infection after CBT. We found that
the incidence and course of CMV infections
were superimposable in the case of D2/R1 CBT
and D2/R1 unrelated or mismatched related donors
(Figures 3-5). In D2/R1 transplants, both from
adult donors and from CB, the incidence of early and
late infections were very similar. Moreover, the time
needed to permanent control of CMV infection
was similar, and was much longer than in D1/R1
transplants. To our knowledge, these similarities of
CMV infections in CBT and alternative D2/R1
recipients have not been reported before, and might,
at least partially, explain the high burden of CMV-
related morbidity after CBT.
The outcome of transplantation depends on several
variables, with infections being an important one. The
consequences of CMV reactivation after HSCT go be-
yond the development of CMV disease and seem to in-
fluence significantly the rate of GVHD, of bacterial and
fungal infections, andOS [2,23]. Although the incidence
of CMV disease and OS in alternative transplant
recipients may vary in different cohorts of patients
(reported rate of CMV disease: 3%-9% and OS
approximately 60%), our results are within the range
reported for this population, and importantly, were
similar in CBT and in alternative donor transplants
[17,23-25]. In our cohort, the characteristics of CMV
infection in both groups had apparently little impact
on CMV disease, TRM, and survival. A low incidence
of repeated CMV infection on mortality might be
because of high efficacy of preemptive treatment in
reducing the incidence of CMV disease. Nevertheless,
4 times longer CMV positivity in CBT results
necessarily in higher morbidity, and a long necessity of
monitoring and treatment, with a consequent worse
98 Biol Blood Marrow Transplant 18:92-99, 2012M. Mikulska et al.quality of life. Indeed, 6months afterHSCT,more than
60% of CBT recipients continued their intravenous
treatment and intensive monitoring of CMV,
compared with only approximately 25% of alternative
transplant recipients (Figure 2).
Various protocols of CMV prophylaxis (high-dose
acyclovir, gancyclovir, etc.) are being used in different
centers, and CMV infection rates differ between the
studies. One of the main advantages of this study is
that this it is an analysis of a homogeneous group of pa-
tients receiving transplants from donors other than
matched related and undergoing exactly the same
CMV prophylaxis and treatment strategy. However,
several limitations of our study should be also acknowl-
edged. In terms of internal validity, there were differ-
ences between 2 groups of patients in underlying
disease, conditioning regimen, andGVHDprophylaxis.
However, none of these variables is known to influence
significantly CMV incidence or severity. More impor-
tant are the limitations potentially hindering extrapola-
tion of our results to different populations. First, this is
a retrospective analysis of data from a single center. Sec-
ond, theMediterranean populations are known for their
high prevalence ofCMV seropositivity; thus, the overall
rate of CMV infections may differ from other groups.
However, data on incidence in seropositive donors are
similar to data reported in the literature and are applica-
ble to other cohorts of seropositive recipients. Third,
the foscavir prophylaxis and combination treatment
strategies are not universally used; thus, the rate of
CMV infections and disease may vary if other prophy-
lactic schemes are used, but the differences between
the subgroups of patients should remain similar.
In conclusion, CMV infections are frequent after
alternative donor transplants. The incidence of CMV
infection, its duration, and the incidence of late infec-
tion are almost identical in D2/R1 alternative donors
andD2/R1CBT recipients. Therefore, the burden of
CMV morbidity seems to be associated with donor
serostatus rather than with CBT-related immunodefi-
ciency. All these differences, however, had little impact
on TRM and OS, which were similar in alternative
transplant and CBT patients who experienced CMV
infections. Further studies are warranted to determine
the best management strategy for a long-lasting
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